Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
JAMA Cardiol. 2019 Oct 1;4(10):1034-1042. doi: 10.1001/jamacardio.2019.2724.
Traditionally, elevated troponin concentrations were synonymous with myocardial infarction. But with improvements in troponin assays, elevated concentrations without overt myocardial ischemia are now more common; this is referred to as myocardial injury. Physicians may be falsely reassured by the absence of myocardial ischemia; however, recent evidence suggests that myocardial injury is associated with even more detrimental outcomes. Accordingly, this article reviews the definition, epidemiology, differential diagnosis, diagnostic evaluation, and management of myocardial injury.
Current epidemiological evidence suggests that myocardial injury without overt ischemia represents about 60% of cases of abnormal troponin concentrations when obtained for clinical indications, and 1 in 8 patients presenting to the hospital will have evidence of myocardial injury. Myocardial injury is a concerning prognosis; the 5-year mortality rate is approximately 70%, with a major adverse cardiovascular event rate of 30% in the same period. The differential diagnosis is broad and can be divided into acute and chronic precipitants. The initial workup involves an assessment for myocardial ischemia. If infarction is ruled out, further evaluation includes a detailed history, physical examination, laboratory testing, a 12-lead electrocardiogram, and (if there is no known history of structural or valvular heart disease) an echocardiogram. Unfortunately, no consensus exists on routine management of patients with myocardial injury. Identifying and treating the underlying precipitant is the most practical approach.
Myocardial injury is the most common cause of abnormal troponin results, and its incidence will likely increase with an aging population, increasing prevalence of cardiovascular comorbidities, and greater sensitivity of troponin assays. Myocardial injury represents a challenge to clinicians; however, given its serious prognosis, it warrants a thorough evaluation of its underlying precipitant. Future strategies to prevent and/or manage myocardial injury are needed.
传统上,肌钙蛋白浓度升高与心肌梗死同义。但随着肌钙蛋白检测方法的改进,现在更常见的是没有明显心肌缺血的浓度升高;这被称为心肌损伤。由于没有明显的心肌缺血,医生可能会错误地感到放心;然而,最近的证据表明,心肌损伤与更不利的结果相关。因此,本文回顾了心肌损伤的定义、流行病学、鉴别诊断、诊断评估和管理。
目前的流行病学证据表明,在获得临床指征时,异常肌钙蛋白浓度中约有 60%没有明显缺血,而 1/8 到医院就诊的患者将有心肌损伤的证据。心肌损伤是一个令人担忧的预后;5 年死亡率约为 70%,同期主要不良心血管事件发生率为 30%。鉴别诊断范围广泛,可分为急性和慢性诱因。初始检查包括评估心肌缺血。如果排除了梗死,进一步评估包括详细的病史、体格检查、实验室检查、12 导联心电图,以及(如果没有已知的结构性或瓣膜性心脏病病史)超声心动图。不幸的是,对于心肌损伤患者的常规管理尚未达成共识。确定和治疗潜在诱因是最实用的方法。
心肌损伤是异常肌钙蛋白结果最常见的原因,随着人口老龄化、心血管合并症患病率增加以及肌钙蛋白检测方法敏感性增加,其发病率可能会增加。心肌损伤对临床医生来说是一个挑战;然而,鉴于其严重的预后,它需要对其潜在诱因进行彻底评估。需要制定未来预防和/或管理心肌损伤的策略。